FungiAlert Competitors

Fungi Perfecti® - makers of Host Defense® Mushrooms™ - is a family-owned company specializing in mushroom mycelium-based supplements. Founded by Paul Stamets in 1980 with the goal of building a bridge between people and fungi, Fungi Perfecti® has become synonymous with cutting-edge mycological research and innovative mycological solutions. Under Paul’s visionary leadership, we have made significant breakthroughs revealing the power and potential of mushroom mycelium. This is the foundation of the Host Defense® brand. Based near the Olympic Rainforest in Washington state, we are one of the best-documented and longest-standing mushroom supplement companies in the USA. Since its inception, Fungi Perfecti® has been the industry leader in research on the endless potential for the use of fungi in everything from water filtration (mycofiltration) and ecological rehabilitation (mycoremediation), to using beneficial mushrooms in the form of supplements to support human health. Our continued mission is to explore, study, preserve, and spread knowledge about the use of fungi for helping people and planet.* *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

BioHarvest Sciences Inc. (Nasdaq: BHST) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 17 years and >$100M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a “target optimized” combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Biologics+ CDMO Services: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, nutrition, cosmetics, and nutraceutical partners to develop proprietary compounds with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has now exceeded 60,000 daily users (>$50M USD Revenue since 2021 launch). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs.

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. We are developing three types of iPSC-derived Natural Killer cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multispecific antibody platform designed to engage natural killer cells by targeting NKp46 using a proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Clinical studies are expected to initiate in 2022. Cytovia’s R&D laboratories in Natick, MA and GMP cell manufacturing facility in Puerto Rico are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia Therapeutics has recently formed CytoLynx Therapeutics, a joint-venture entity focused on research and development, manufacturing, and commercialization activities in Greater China and beyond. Find out more at www.cytoviatx.com.